Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

3.080 -0.010 (-0.32%)
Official Closing Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Revance Therapeutics

< Previous 1 2 3 4 5 6 Next >
3 Very Oversold Biotech Stocks to Buy Right Now
These biotech stocks have tumbled a great deal in recent months, but their long-term outlooks remain quite strong. 
Via InvestorPlace
3 Very Oversold Pharma Stocks to Buy Right Now
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
How Revance Is Taking A Page Out Of AbbVie's Botox Playbook
The company sells a cosmetic treatment. Now, it's bridging into neuroscience. 
Via Investor's Business Daily
Where Revance Therapeutics Stands With Analysts
Via Benzinga
Earnings Preview: Revance Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
Analyst Expectations for Revance Therapeutics's Future
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Healthcare Stocks to Make You the Millionaire Next Door
For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy. 
Via InvestorPlace
Earnings Preview For Revance Therapeutics
Via Benzinga
7 Analysts Have This to Say About Revance Therapeutics
Via Benzinga
7 Stocks to Buy for the Massive Rally Ahead
With economic growth poised to exceed expectations in 2023, here are seven stocks to buy for a market rally. 
Via InvestorPlace
3 Pharma Stocks That Will Mint Millionaires
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
What 4 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Macy's, Acuity Brands And 3 Stocks To Watch Heading Into Monday
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Revance Therapeutics's Earnings: A Preview
Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Revance... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
What 7 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.